1 Löffler W. Endocarditisparietalisfibroplastica mit Bluteosinophilie. Schweiz Med Wschr. 1936;66:817.
2 Holzmann M. Klinische Elektrokardiographie. 5. Auflage,
G. Thieme Verlag, Stuttgart, 1965.
3 Rutishauser W. . Cardiovasc Med. 2014;17:256–65.
4 Mahler F. Zum Gedenken an einen Pionier der Angiologie –
Prof. Dr. med. Alfred Bollinger (1932–2015). Cardiovasc Med. 2015;18:201–2.
5 Rutishauser W. . Cardiovasc Med. 2014;17:289–92.
6 Säuberli HA. Ake Senning Pionier der Schweizer Herzchirurgie
in Zürich. Cardiovasc Med. 2011;14:109–10.
7 Meier B, Bachmann D, Lüscher TF. 25 years of coronary angioplasty: almost a fairy tale. Lancet. 2003;361:527.
8 Ricci R, Sumara G, Sumara IJ, Rosenberg I, Kurrer M, Akhmedov A, et al. JNK2 is required for scavenger receptor-A mediated foam
cell formation and atherosgenesis. Science. 2004;306:1558–61.
9 Lüscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, von Segesser L, et al. Difference between Endothelium-Dependent Relaxation in Arterial and in Venous Coronary Bypass Grafts.
N Engl J Med. 1988;319:462–7.
10 Steffel J, Lüscher TF, Tanner FC. Tissue factor and cardiovascular diseases. Molecular mechanisms and clinical implications. Circulation. 2006;113:722–31.
11 van der Loo B, Labugger R, Skepper JN, Bachschmid M, Kilo J, Powell JM, et al. Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med. 2000;192:1731–43.
12 Camici GG, Savarese G, Akhmedov A, Lüscher TF. Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease. Eur Heart J. 2015;21;36(48):3392–403.
13 Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, et al. Mechanisms underlying adverse effects of highdensity lipoprotein on endothelial NO synthaseactivating pathways in coronary artery disease. J Clin Invest. 2011;121:2693–708.
14 Lüscher TF, Landmesser U, von Eckardstein A, Fogelman AM. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res. 2014;3;114(1):171–82.
15 Xinmin S. Li, Slayman Obeid, Roland Klingenberg, Baris Gencer, François Mach, Lorenz Räber, et al. Gutmicrobiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J. 2017; in press.
16 Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016;37:1967–76.
17 Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, et al. N Engl J Med. 2015;3;373(10):929–38.
18 Anand IS, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, et al. on behalf of the EARTH investigators. Long-term Effects of darusentan on LV remodeling and clinical outcomes – The Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH). Lancet. 2004;364:347–54.
19 SD, J, G, R, K, H, et al.; . Ferric carboxymaltose in patients with heart failure and iron deficiency. 2009;361:2436–48.
20 Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, et al. Holzmeister for the EchoCRT Study Group. Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex.
N Engl J Med. 2013;369:395–405.
21 Lüscher TF. Chefredaktion «Cardiovascular Medicine» ab 2017. Cardiovasc Med. 2016;19:307–8.